SCHEMBL298707

SCHEMBL298707

O=C(c1cccc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)c1)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 2/20 0.46
MAPT P10636 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
BRAF P15056 4/20 0.45
POLB P06746 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 1/20 0.45
BRD4 O60885 1/20 0.44
ITGA1 P56199 1/20 0.44
BTK Q06187 1/20 0.44
ERAP1 Q9NZ08 1/20 0.43
CYP3A4 P08684 1/20 0.43
BMPR1B O00238 1/20 0.43
PLK4 O00444 1/20 0.43
PIR O00625 1/20 0.43
AURKA O14965 1/20 0.43
DCLK1 O15075 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297843 0.92 GAA (0.48) MAPTMEN1KMT2AHTTBRAF
SCHEMBL298085 0.91 CYP19A1 (0.49) CCR9MEN1KMT2ABRAFPOLB
SCHEMBL298104 0.90 CYP2C9 (0.53) MAPTMEN1KMT2AHTTBRAF
SCHEMBL298889 0.89 CCR9 (0.50) CCR9BRAFCYP2C9CYP2C19ITGA1
SCHEMBL299148 0.86 BRAF (0.49) CCR9BRAFCYP2C9CYP2C19CYP3A4
SCHEMBL3710534 0.86 CYP3A4 (0.57) MAPTBRAFPOLBCYP2C9CYP2C19
SCHEMBL298675 0.86 BRAF (0.49) CCR9MAPTMEN1KMT2AHTT
SCHEMBL3709466 0.86 PGR (0.50) MEN1KMT2ABRAFCYP2C9CYP2C19
SCHEMBL298399 0.84 BRAF (0.45) CCR9BRAFCYP2C9CYP2C19BTK
SCHEMBL7875675 0.84 BRD4 (0.42) MAPTMEN1KMT2APOLBCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CCR9 3946/4885MAPT 3733/4885MEN1 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.